Molly O. Regelmann
Pediatric Endocrinology
<p>Dr. Regelmann is an Assistant Professor of Pediatric Endocrinology and Diabetes at the Children’s Hospital at Montefiore. She formerly held the same position at the Icahn School of Medicine at Mount Sinai, where she established herself for clinical excellence, being named a New York Rising Stars Super Doctor and Castle Connolly Top Doctor.</p><p>Dr. Regelmann graduated magna cum laude with high honors in research from Cornell University. She received her medical education at New York University. She completed residency training in general pediatrics and fellowship training in pediatric endocrinology at the Icahn School of Medicine at Mount Sinai.</p>
Allison K. Paul
Shadi Nahvi
<p>Dr. Shadi Nahvi is Professor (with tenure) in the Departments of Medicine and Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine, and directs the General Internal Medicine and Addiction Medicine Fellowship Programs. Her research focuses on optimizing quality of life and health outcomes among persons with substance use disorder.</p>
<p>Dr. Nahvi’s research is grounded in nearly two decades of clinical experience as a primary care physician caring for persons with opioid and other substance use disorders. Her primary research focus is optimizing the efficacy and delivery of tobacco cessation treatments among persons with co-occurring substance use disorders. Currently, she is Principal Investigator of a NIDA R01-funded randomized, 2 x 2 factorial trial of directly observed and long-term varenicline treatment among smokers with opioid use disorder. She has also led a KL2 Career Development Award-funded, randomized, placebo-controlled pilot trial of varenicline for smoking cessation among smokers with co-morbid substance use disorder, a study of health system-level interventions to increase documentation and treatment of tobacco use among substance use disorder counselors, and a randomized trial of the efficacy of directly observed varenicline provided at a methadone clinic for promoting smoking cessation and enhancing adherence. </p>
<p>Dr. Nahvi graduated from the Brown University School of Medicine in 2001 and completed residency training in Primary Care Internal Medicine at Bellevue Hospital and New York University Medical Center in 2004. She then joined the faculty in the Albert Einstein College of Medicine Division of Substance Abuse as the Medical Director of an opioid treatment program.</p>
<p>Dr. Nahvi has served on numerous national advisory committees, including serving as a member of the NY State Department of Health AIDS Institute’s Guideline Committee for the Care of Substance Users and a Steering Committee member of the NY State Department of Health AIDS Institute's Tobacco Cessation Improvement Campaign.</p>
* Improving health outcomes and quality of life of persons with substance use disorders
<p>Selected recent publications:</p>
<p>Nahvi S, Segal KS, Litwin AH, Arnsten JH. Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics. <em>Addiction Science and Clinical Practice. </em>2014, 13;9:9</p>
<p class="Normal">Nahvi S, Blackstock O, Sohler NL, Thompson D, Cunningham CO. Smoking cessation treatment among office-based buprenorphine treatment patients. <em>Journal of Substance Abuse Treatment. </em>2014, 47(2):175-9</p>
<p>Nahvi S, Ning Y, Segal KS, Richter KP, Arnsten JH. Varenicline efficacy and safety among methadone maintained smokers: A randomized placebo-controlled trial. <em>Addiction. </em>2014, 109(9):1554-63</p>
<p>Griffin J, Segal KS, Arnsten JH, Nahvi S. Barriers to telephone quitline use among methadone maintained smokers. <em>Nicotine & Tobacco Research.</em> 2015,17(8):931-6</p>
<p>Batchelder AW, Peyser D, Nahvi S, Arnsten JH, Litwin AH. "Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to Hepatitis C treatment. <em>Drug and Alcohol Dependence.</em> 2015, 153:66-71</p>
<p>Maradiaga J, Nahvi S, Cunningham CO, Sanchez J, Fox AD. "I kicked the hard way. I got incarcerated." Withdrawal from methadone during incarceration and subsequent aversion to medication assisted treatments. <em>Journal of Substance Abuse Treatment.</em> 2016, 62:49-54</p>
<p>Fitzgerald SA, Faseru B, Mussulman L, Howser E, Nahvi S, Goggin K, Cooperman NA, Richter KP. Improving quality of care for hospitalized smokers with HIV: Tobacco dependence treatment referral and utilization. <em>The Joint Commission Journal on Quality and Patient Safety.</em> 2016, 42(5):219-24</p>
<p>Shah PA, Cunningham CO, Blackstock OJ, Brisbane MT, Nahvi S. Use of smoking cessation methods among patients receiving office-based buprenorphine maintenance treatment. <em>Journal of Addiction Medicine.</em> 2017, 11(6):494-497</p>
<p>Adams TR, Arnsten JH, Ning Y, Nahvi S. Feasibility and preliminary effectiveness of varenicline for treating co-occurring cannabis and tobacco use. <em>Journal of Psychoactive Drugs.</em> 2018, 50(1):12-18</p>
<p>Sohler NL, Starrels J, Khalid L, Bachhuber M, Arnsten JH, Nahvi S, Jost J, Cunningham CO. Marijuana use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain. <em>Substance Use and Misuse. </em>2018, 17:1-6</p>
<p>Minami H, Brinkman HR, Nahvi S, Arnsten JH, Rivera-Mindt M, Wetter DW, Litvin Bloom E, Price LH, Vieira C, Donnelly R, McClain LM, Kennedy KA, D'Aquila E, Fine M, McCarthy DE, Thomas JG, Hecht J, Brown RA. Rationale, design and pilot feasibility results of a smartphone-assisted, mindfulness-based intervention for smokers with mood disorders: Project mSMART MIND. <em>Contemporary Clinical Trials. </em>2018, 66:26-44</p>
<p>Weinberger AH, Pacek LR, Wall MM, Zvolensky MJ, Copeland J, Galea S, Nahvi S, Moeller SJ, Hasin DS, Goodwin RD. Trends in cannabis use disorder by cigarette smoking status in the United States, 2002 to 2016. <em>Drug and Alcohol Dependence.</em> 2018, 191:45-51</p>
<p>Nahvi S, Arnsten JH. Missed opportunities to test the neuropsychiatric safety--and efficacy--of varenicline among smokers with substance use disorders. <em>Drug and Alcohol Dependence. </em>2018, 185: 245-247.</p>
Haleh Moazen
Courtney A. McNamara
<p>Courtney McNamara, MD, is Associate Program Director, Pediatric Residency Program at the Children’s Hospital at Montefiore Einstein (CHAM) and Assistant Professor, Pediatrics at our Albert Einstein College of Medicine. Her clinical focus is on pediatric hospital medicine, with a particular interest in resident education and mentorship.</p><p>In 2006, Dr. McNamara received her Bachelor of Science at James Madison University. She pursued her medical education at New York Medical College, earning her Doctor of Medicine in 2010. She then came to CHAM for her postgraduate training, completing her pediatric residency in 2013.</p><p>Dr. McNamara’s research focuses on improving the patient experience. She is a co-investigator in a grant funded project investigating communication with hospitalized patients with limited English proficiency, and her body of research includes quality improvement research studies focused on improving inpatient pediatric comfort and decreasing painful experiences. She has shared her work through peer-reviewed journals, abstracts, poster presentations and platform presentations.</p><p>Dr. McNamara is board certified in both General Pediatrics and Pediatric Hospital Medicine by the American Board of Pediatrics. She is a member of the American Academy of Pediatrics. In 2023, Dr. McNamara was inducted into the Leo M. Davidoff Society.</p>
Beth N. McLellan
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Beth McLellan graduated with honors from Northwestern University and attended medical school at Wayne State University where she graduated with Alpha Omega Alpha honors. She completed an internship in Internal Medicine at Loyola University Health System and her Dermatology residency at Henry Ford Health System in Detroit where she also served as Chief Resident. She currently is a Professor in the Department of Medicine (Dermatology) and has served as Chief of the Division of Dermatology since 2020.</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. McLellan specializes in complex medical Dermatology and has a special interest in Supportive Oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair, and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis as well as successful use of bacterial decolonization for prevention of radiation dermatitis. She has published numerous articles and textbook chapters related to Supportive Oncodermatology and is regularly invited to speak at Dermatology and Oncology conferences for physicians and patients including the annual meeting of the American Academy of Dermatology, ASCO, and Gilda's Club.</span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Playing an active role in the Dermatology Residency, Dr. McLellan is the director of resident research and regularly lectures residents and medical students. She has served as a mentor to many residents and students and directs a year-long Oncodermatology research fellowship for medical students taking a year off for research. Interested medical students can learn more about the fellowship here: https://www.einsteinmed.edu/departments/medicine/divisions/dermatology/…;
<div> </div>
<div> </div>
<div> </div>
<p> </p>
Chemotherapy Side Effects
Scalp Cooling
Dr. McLellan specializes in complex medical dermatology and has a special interest in supportive oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.
Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis
<p>Beth N. McLellan, MD, is Chief, Dermatology, Director, Supportive Oncodermatology and Professor, Dermatology at Montefiore Einstein. She specializes in complex medical dermatology and has a special interest in supportive oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.</p><p>After earning her Doctor of Medicine at Wayne State University, Dr. McLellan completed an internship in internal medicine at Loyola University Health System and her dermatology residency at Henry Ford Health System where she also served as chief resident and initiated a supportive oncodermatology clinic. Dr. McLellan received additional oncodermatology training at Memorial Sloan Kettering Cancer Center and at the Institut Gustave Roussy in Paris, France.</p><p>Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis. Playing an active role in the Montefiore Einstein Dermatology Residency, Dr. McLellan is the Director of Resident Research and regularly lectures residents and medical students at both dermatology and oncology meetings. She has served as a mentor to many residents and students and directs a year long oncodermatology research fellowship for medical students taking a year off for research. Dr. McLellan has published numerous articles and textbook chapters related to supportive oncodermatology and is regularly invited to speak at dermatology and oncology conferences for physicians and patients, including the annual meeting of the American Academy of Dermatology, American Society of Clinical Oncology and Gilda's Club.</p><p>As part of her commitment to treating the whole patient, Dr. McLellan founded the New York Vitiligo Support Group. She has received awards from the Dermatology Foundation.</p>
Sofya Maslyanskaya
<p>Sofya Maslyanskaya MD is an Assistant Clinical Professor of Pediatrics at the Albert Einstein College. Dr. Maslyanskaya earned her bachelor’s degree in biochemistry from Stony Brook University in 2004 and her medical degree from SUNY Downstate College of Medicine in 2008. She completed her pediatrics residency at New York University and her fellowship in adolescent medicine at the Children’s Hospital at Montefiore in June, 2014. Dr. Maslyanskaya is board-certified in Pediatrics and Adolescent Medicine.</p>
<p>She is a Member of the American Academy of Pediatrics (AAP), and a member of the Society for Adolescent Health and Medicine (SAHM) and the SAHM electronic health committee and the North American Society for Pediatric and Adolescent Gynecology (NASPAG). </p>
<p>Dr. Maslyanskaya provides adolescent sub-specialty care at the Childrens Hospital at Montefiore (CHAM) and Montefiore Hutch Dr. Maslyanskaya is the medical director of the Long Acting Reversible Contraceptive (LARC) service at CHAM.</p>
<p>Clinical Focus:</p>
<p>Adolescent reproductive health, long acting reversible contraception (LARC) use, menstrual disorders, eating disorders, quality improvement</p>
<p><span>Research Focus:</span></p>
<p><span>Adolescent reproductive health, LARC use in adolescents, quality improvement in the care of adolescents </span></p>
Dr. Maslyanskaya’s clinical focus is on adolescent gynecology and adolescent reproductive healthcare.
Dr. Maslyanskaya’s research interests include contraceptive care for adolescent patients and counseling and provision of long-acting reversible contraceptives for adolescents.
<p>Sofya Maslyanskaya, MD, is the Medical Director of the Adolescent Medicine Outpatient Practice and an Attending Physician in the Division of Adolescent Medicine at Children’s Hospital at Montefiore. She is also an Assistant Professor of Pediatrics at our Albert Einstein College of Medicine. Dr. Maslyanskaya’s clinical focus is in adolescent gynecology and adolescent reproductive healthcare. She is also interested in the medical management of adolescent eating disorders. Dr. Maslyanskaya joined Montefiore in 2014.</p><p>Dr. Maslyanskaya received her Bachelor of Science in Biochemistry in 2004 at Stony Brook University. In 2008, Dr. Maslyanskaya received her Doctor of Medicine from SUNY Downstate College of Medicine. She completed her residency in Pediatrics at New York University in 2011, followed by a post-doctoral fellowship in Adolescent Medicine at Children’s Hospital at Montefiore and Albert Einstein College of Medicine.</p><p>Dr. Maslyanskaya’s research interests include contraceptive care for adolescent patients and counseling and provision of long-acting reversible contraceptives for adolescents. Her work has been published in several peer-reviewed journals, review articles and chapters in textbooks.</p><p>In 2013, Dr. Maslyanskaya was inducted into the Leo M. Davidoff Society of the Albert Einstein College of Medicine in recognition of outstanding contributions to medical student education as a post-doctoral fellow.</p><p>Dr. Maslyanskaya is board certified in Pediatrics and Adolescent Medicine by the American Board of Pediatrics and is a member of the American Academy of Pediatrics. </p>
Ranon E. Mann
As Program Director my clinical focus is patient care and resident education. My interests surround<br />complex medical dermatology.
Research focus on skin disorders affecting patients who are HIV positive.